Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis

por Nakaya, Y, Shide, K, Naito, H, Niwa, T, Horio, T, Miyake, J, Shimoda, K
Publicado 2014

All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors

por Mihara, K, Yoshida, T, Ishida, S, Takei, Y, Kitanaka, A, Shimoda, K, Morishita, K, Takihara, Y, Ichinohe, T
Publicado 2016

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

por Nakaya, Y, Shide, K, Niwa, T, Homan, J, Sugahara, S, Horio, T, Kuramoto, K, Kotera, T, Shibayama, H, Hori, K, Naito, H, Shimoda, K
Publicado 2011

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA

por Kirito, K., Edahiro, Y., Ohishi, K., Gotoh, A., Takenaka, K., Shibayama, H., Shimizu, T., Usuki, K., Shimoda, K., Ito, M., VanWart, S. A., Zagrijtschuk, O., Qin, A., Kawase, H., Miyachi, N., Sato, T., Komatsu, N.
Publicado 2022

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

por Shide, K, Kameda, T, Yamaji, T, Sekine, M, Inada, N, Kamiunten, A, Akizuki, K, Nakamura, K, Hidaka, T, Kubuki, Y, Shimoda, H, Kitanaka, A, Honda, A, Sawaguchi, A, Abe, H, Miike, T, Iwakiri, H, Tahara, Y, Sueta, M, Hasuike, S, Yamamoto, S, Nagata, K, Shimoda, K
Publicado 2017